lilly glp-1 Eli stock soars on encouraging results for daily weight-loss pill Lilly's GLP-1 Surge Dwarfs Abbott's

GLP-1 receptor agonists are widely expressed in the brain, playing a role in reward and addiction pathways

Fifty-eight per cent of people taking or considering taking GLP-1 drugs said weight loss was their main driver, while 42 per cent said diabetes was their primary reason

Published 2023 Jun 18

Federal law says Part D plans can't cover drugs prescribed for weight loss even though obesity is a serious health condition

The Discovery of GLP-1 The story of GLP-1 began in the 1980s, a decade marked by significant advancements in biomedical research

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy